Companies SpyGlass Pharma
SpyGlass Pharma (SGP): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me SpyGlass Pharma’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,035,047FY2024
- $3,322,711FY2025
CEO total pay was $3,322,711 in fiscal 2025, up from $1,035,047 in fiscal 2024.
FY2025: salary $444,544,000 · bonus $0 · stock awards $0 · option awards $2,662,934,000
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Patrick Mooney | $444,544,000 | $0 | $0 | $2,662,934,000 | $215,088,000 | $0 | $0 | $3,322,711 |
| Chief Executive Officer | ||||||||
| Malik Kahook | 0 | 0 | 0 | 2,060,244,000 | 125,975,000 | 0 | 298,250,000 | 2,484,469 |
| President, Chief Medical Officer and Executive Chair | ||||||||
| Chetan Pujara | 355,250,000 | 0 | 0 | 1,049,292,000 | 126,289,000 | 0 | 9,521,000 | 1,539,952 |
| Chief Research & Development Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Patrick Mooney | $3,322,711 | $1,035,047 | — | ↑ +2,287,664 |
| Malik Kahook | 2,484,469 | 379,454 | — | ↑ +2,105,015 |
| Chetan Pujara | 1,539,952 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation philosophy is designed to provide appropriate incentives to executives to achieve defined performance goals and to reward individual achievement towards these goals, while equity-based incentive awards are designed to align the interests of the company and its stockholders with those of employees and consultants.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | false |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chetan Pujara | Option | 31,397 | 2.87 | — |
| Malik Kahook | Option | 33,179 | 2.18 | — |
| Chetan Pujara | Option | 34,798 | 7.11 | — |
| Patrick Mooney | Option | 79,152 | 2.18 | — |
| Patrick Mooney | Option | 106,571 | 2.18 | — |
| Patrick Mooney | Option | 126,986 | 2.87 | — |
| Chetan Pujara | Option | 153,219 | 2.18 | — |
| Malik Kahook | Option | 170,475 | 7.11 | — |
| Malik Kahook | Option | 191,874 | 2.87 | — |
| Patrick Mooney | Option | 329,784 | 7.11 | — |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Peer group, and who names SpyGlass Pharma as a peer
Companies that benchmark against SGP
No companies currently name SGP as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | SpyGlass Pharma | 2025 | Patrick Mooney | $444,544,000 | $0 | $2,662,934,000 | $215,088,000 | $3,322,711 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (5 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Patrick Mooney. 10-K, filed 2026-03-26. Section “Executive Compensation” · page 122. As printed: 3,322,711. View filing ↗
- Section 01, Malik Kahook. 10-K, filed 2026-03-26. Section “Executive Compensation” · page 122. As printed: 2,484,469. View filing ↗
- Section 01, Chetan Pujara. 10-K, filed 2026-03-26. Section “Executive Compensation” · page 122. As printed: 1,539,952. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- SpyGlass Pharma (subject), Section 10b CEO total. 10-K, filed 2026-03-26. CEO total compensation as printed in SpyGlass Pharma's own proxy. As printed: 3,322,711. View filing ↗